Viela Bio, Mitsubishi Tanabe sign licensing deal for inebilizumab

This article was originally published here

Inebilizumab will be developed and marketed in the Asian regions for the treatment of neuromyelitis optica spectrum disorder (NMOSD), and also other potential indications in the future. As

The post Viela Bio, Mitsubishi Tanabe sign licensing deal for inebilizumab appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply